Relapsed Acute Lymphoblastic Leukemia (ALL) Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Back to Relapsed Acute Lymphoblastic Leukemia (ALL)

Also known as: Acute Lymphoblastic Leukemia, in Relapse / Relapsed ALL / Relapsed Acute Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0069491 (Relapsed Acute Lymphoblastic Leukemia (ALL))	Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05310591	Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence	Treatment	Nivolumab (DB09035)